Resistance to acetylsalicylic acid in patients after ischemic stroke

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 12, 2008, Pages 727-733

  Zytkiewicz, Marcin ^a,c   Giełwanowska, Liwia ^b   Wojtasińska, Ewelina ^b   Psuja, Piotr ^a   Zawilska, Krystyna ^b  

^a Department of Internal Diseases   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Oddzial Chorob Wewnetrznych   (Poland)

Author keywords

PFA 100; Platelet aggregation; Resistance to ASA; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALPHA2 INTEGRIN; ARACHIDONIC ACID; COLLAGEN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING PARAMETERS; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; GENETIC CORRELATION; GENETIC POLYMORPHISM; HEREDITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE AGGREGATION;

EID: 58449104742     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.540     Document Type: Article

References (36)

1. Gurbel P, Antonino M, Tatry U. Antiplatelet treatment of cardiovascular disease: a transtational research perspective. Pol Arch Med Wewn. 2008; 118: 289-297.
2. Sane DC, McKee SA, Malilin Al, et al. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol. 2002; 90: 893-895.
3. Kottke-Marchant K, Murugesan G, Gerber C, et al. High prevalence of aspirin resistance in patients with a history of myocardial infarction. J Thromb Haemost. 2003; Suppl 1: 243.
4. Hezard N, Metz D, Drouille C, et al. Increasing dosage of aspirin before percutaneous coronary intervention: is there any effect in aspirin resistant patients? A randomized study. J Thromb Haemost. 2003; Suppl 1: P0242.
5. Paton RC. Platelet survival in diabetes mellitus using an aspirin-labeling technique. Thromb Res. 1979; 15: 793-798.
6. Santoso S, Kunicki TJ, Kroll H, et al. Association of the platet glycoprotein la C807 T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 1999; 93: 2449-2453.
7. Dudman N, Guo Xue-Wei, Gordon R, et al. Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J Nutr. 1996; 126: 1295-3000.
8. Guthikonda S, Lev El, Kleiman NS. Resistance to antiplatelet therapy. Curr Cardiol Rep. 2005; 7: 242-248.
9. Szczeklik A, Lindas A. More on aspirin resistance. J Thromb Haemost. 2004; 2: 1489.
10. Szczeklik A, Musial J, Undas A, et al. Aspirin resistance. J Thromb Haemost. 2005; 3: 1655-1662.
11. Szczeklik A, Musial J, Lindas A, et al. Aspirin and thrombinogenesis. Thromb Res. 2003; 110: 345-347.
12. Schwartz KA, Schwartz DE, Baber KR, et al. Aspirin resistance: do not confuse it with noncompliance. J Lab Clin Med. 2002; 139: 227.
13. Heitzer T, Ollmann I, Köke K, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003; 108: 542-547.
14. Frelinger AL, Furman Ml, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-2 independent pathway. A 700-patient study of aspirin resistance. Circulation. 2006; 113: 2888-2896.
15. Freedmann MD, Jane E. The aspirin resistance controversy. Clinical entity or platelet heterogeneity. Cirulation. 2006; 133: 2865-2867.
16. Schwammenthal Y, Tsabari R, Matetzky S, et al. Low rate of responsiveness to ASA in acute brain ischemia: association with stroke severity and clinical outcome. J Thromb Haemost. 2005; 3 (Suppl 1): P198.
17. Eikelboom JW, Hirsh J, Weitz J. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002; 105: 1650-1655.
18. Lukasik M, Luzak B, Watala C, et al. Effect of the 807 C/T polymorphism in platelet glycoprotein la on the relationship between carotid artery intima-media thickness and platelet activation. J Thromb Haemost. 2005; 3(Suppl 1): P344.
19. Santoso S, Kunicki TJ, Kroll H, et al. Association of the platet glycoprotein la C807 T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 1999; 93: 2449-2453.
20. Leone M, Gresele P. Detection of critical degree of platelet T×A2 - production inhibition by the PFA 100 in aspirin-treated subjects: possible relevance for the monitoring of aspirin resistance. J Thromb Haemost. 2005; 3 (Suppl 1): P964.
21. Harrison P Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke. 2005; 36: 1001.
22. Chaudhary KJ, Prasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol. 1991; 72: 1-7.
23. Morrow JD, Frei B, Longmire AW. Increase in circulating products of lipid peroxidation (F2-izoprostanes) in smokers. N Engl J Med. 1995; 332: 1198-1203.
24. Akoglu B, Milovic V, Caspary WF, et al. Hyperproliferation of homocysteine-treated colon cancer cells is reversed by folate and 5-methyltetra-hydrofolate. Eur J Nutr. 2004; 43: 93-99.
25. Chen P. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul. 1999; 39: 93-109.
26. Ryglewicz D., Graban A. [Disturbances of Homocysteine Metabolism in Degenerative Diseases of the Nervous System). Czynniki Ryzyka. 2005; 11: 20-22. Polish.
27. Lentz S, Sadler J. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991; 88: 1906-1914.
28. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood. 1992; 79: 2930-2936.
29. Perry IJ. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995; 346: 1395-1398.
30. Stryczyński L, Pra̧tnicka-Rozynek M, Turowiecka Z, et al. [Disturbances of Haemostasis in Patients after Ischemic Stroke in Early Age). Nowiny Lekarskie. 2001; 70 (Suppl II): 182-188. Polish.
31. Van-der-Berg M, Boers G, Franken D, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995; 25: 176-181.
32. Zsamboki-Toth E, Beres BJ, Vargova K, et al. Statins do not interfere with the antiplatelet effect of loading dose of clopidogrel in patients with ischemic heart disease. J Thromb Haemost. 2005; 3 (Suppl 1): P1093.
33. Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001; 119: 300-320.
34. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002; 324: 71-86.
35. Michos ED, Ardehali R, Blumenthal RS, et al. Aspirin and clopidogrel resistance. Mayo Clin Proc. 2006; 81: 518-526.
36. Zawilska K, Gaik I, Hanszke E, et al. [Resistance to Antiplatelet Therapy and C807T Glycoprotein la Polymorphism and hyperhomocysteinemia in Patients after Myocardial Infarction). Acta Angiol. 2006; 12 (Suppl A): 130-131.